Xmet-Trio 500/0.2/1 Tablet ER
Marketer
Glenmark Pharmaceuticals Ltd
Salt Composition
Glimepiride (1mg) + Metformin (500mg) + Voglibose (0.2mg)
Overview Xmet-Trio 500/0.2/1 Tablet ER
Glycemic-Trio 500/0.2/1 Extended-Release Tablet is classified as an antidiabetic medication. This combination therapy is indicated for managing type 2 diabetes in adults, effectively regulating blood glucose levels. Glycemic-Trio 500/0.2/1 Extended-Release Tablet should be ingested with meals, consistently at the same time daily for optimal efficacy. Dosage is determined by your physician and may be adjusted based on your blood sugar response. Continued use is crucial, even with controlled blood sugar, as abrupt cessation can lead to hyperglycemia, potentially resulting in kidney complications, vision impairment, neuropathy, and limb loss. This medication forms part of a comprehensive diabetes management plan incorporating a balanced diet, regular physical activity, and weight management as directed by your doctor. Lifestyle modifications are essential for diabetes control. Hypoglycemia (low blood sugar) is a common side effect. Learn to recognize its symptoms—sweating, dizziness, headache, tremors—and know how to treat it promptly. Regular meals and readily available fast-acting glucose sources (e.g., sugary foods, fruit juice) are crucial. Alcohol consumption increases hypoglycemia risk and should be avoided. Other potential side effects include altered taste, nausea, diarrhea, abdominal discomfort, headache, edema, blurred vision, bone fractures, and upper respiratory infections. Weight gain may occur. This medication is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, or severe hepatic or renal impairment. Individuals with a history of cardiovascular disease should inform their physician before initiating treatment. Pregnant or lactating women should seek medical counsel before use. Regular blood glucose monitoring is necessary, and your doctor may order blood tests to monitor blood cell counts and liver function.
Primary Ingredients of Xmet-Trio 500/0.2/1 Tablet ER
No text was provided. Please provide the text you would like me to rewrite.
Uses of Xmet-Trio 500/0.2/1 Tablet ER
Managing type 2 diabetes
Major Benefits of Xmet-Trio 500/0.2/1 Tablet ER:
Consume this medication precisely as prescribed by your physician, adhering to both the dosage and treatment duration. Ingest the entire tablet without chewing, crushing, or fracturing it. Administer Xmet-Trio 500/0.2/1 Tablet ER on an empty stomach.
Common Side effects of Xmet-Trio 500/0.2/1 Tablet ER:
- Nausea
- Diarrhea
- Abdominal pain
- Hypoglycemia (low blood glucose level)
- Loss of appetite
How to use Xmet-Trio 500/0.2/1 Tablet ER:
Follow your doctor's instructions precisely regarding the dosage and treatment length of this medication. Ingest the entire tablet; do not crush, chew, or divide it. Administer Xmet-Trio 500/0.2/1 Tablet ER on an empty stomach.
How Xmet-Trio 500/0.2/1 Tablet ER works:
Extended-release Xmet-Trio tablets (500/0.2/1 mg) contain a triple-drug formulation for diabetes management.
SAFETY ADVICE
AlcoholUNSAFE
Combining Xmet-Trio 500/0.2/1 Tablet ER and alcohol is unsafe.
PregnancyCONSULT YOUR DOCTOR
The extended-release Xmet-Trio 500/0.2/1 tablet may pose pregnancy risks. While human data is scarce, animal research indicates potential harm to a fetus. A physician will assess the advantages against possible risks prior to prescribing. Seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
The extended-release combination tablet Xmet-Trio (500/0.2/1 mg) is likely unsafe for breastfeeding mothers. Available human data indicates potential transfer to breast milk, posing a risk to the infant.
DrivingCAUTION
Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.
KidneyUNSAFE
The extended-release formulation of Xmet-Trio 500/0.2/1 Tablet is likely unsafe for individuals with kidney impairment and its administration should be prevented. Medical advice is recommended. Moreover, Xmet-Trio 500/0.2/1 Tablet ER is unsuitable for patients exhibiting severe kidney dysfunction.
LiverCAUTION
Patients with liver impairment should use Xmet-Trio 500/0.2/1 Tablet ER cautiously, potentially requiring dosage modification. Medical advice is essential. For those with mild to moderate liver disease, Xmet-Trio 500/0.2/1 Tablet ER is typically initiated at a low dose; however, its use is contraindicated in patients with severe hepatic dysfunction.
What if you forget to take Xmet-Trio 500/0.2/1 Tablet ER :
Should you forget to take your Xmet-Trio 500/0.2/1 Tablet ER, administer it immediately upon remembrance. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Xmet-Trio 500/0.2/1 Tablet ER
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Diabetes Management |
3,018 People bought this recently